InsiderClue
← All stocks

Black Diamond Therapeutics, Inc.

BDTX Net buying
CIK 0001701541 #4227 in the set updated 19 Sep 2026
Bought (120 mo)
$105.50M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$41.09M
$167.50K on a plan · $4.19M straight out of an exercise
Sold at will
$36.73M
140 of 190 sales
Net
+$64.41M
+$68.77M against sales at will

By person

23 insiders · 228 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Behbahani Ali
Director
$20.20M (2)
—
+$20.20M
11,448,800
19.93%
$24.24M
+66.0%
Shah Rajeev M.
Director
$19.00M (3)
—
+$19.00M
311,926
0.5429%
$660.32K
—
BIOTECH GROWTH N V
10% owner
$19.68M (15)
$12.00M (7)
+$7.68M
2,733,547
4.76%
$5.79M
−26.8%
Flynn James E
10% owner
$7.60M (1)
—
+$7.60M
778,790
1.36%
$1.65M
—
Bolzon Bradley J PhD
Director
$17.00M (4)
$11.67M (66)
+$5.33M
402,793
0.7011%
$852.67K
—
RA CAPITAL MANAGEMENT, L.P. entity
Director
$4.68M (1)
—
+$4.68M
3,213,828
5.59%
$6.80M
+41.1%
Versant Venture Capital VI, L.P. entity
10% owner
$17.00M (4)
$13.07M (67)
+$3.93M
4,107,283
7.15%
$8.69M
—
Epstein David M.
SEE REMARKS
—
$1.67M (8) scheduled
−$1.67M
688,002
1.20%
$1.46M
+44.5%
Hatzis-Schoch Brent
SEE REMARKS
$57.00K (1)
$1.37M (22) scheduled
−$1.31M
83,400
0.1452%
$176.55K
—
Roberts Christopher D.
Chief Scientific Officer
—
$825.21K (14) scheduled
−$825.21K
3,200
0.0056%
$6.77K
—
Leggett Thomas
Chief Financial Officer
—
$495.61K (6) scheduled
−$495.61K
0
0.0000%
$0.00
—
INGRAM ROBERT ALEXANDER
FORMER DIRECTOR
$152.29K (1)
—
+$152.29K
42,854
0.0746%
$90.72K
—
Ni Fang
SEE REMARKS
$133.38K (3)
—
+$133.38K
125,389
0.2182%
$265.44K
+184.8%
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
10% owner
—
—
—
568,185
0.9889%
$1.20M
—
Buck Elizabeth
CHIEF SCIENTIFIC OFFICER
—
—
—
170,192
0.2962%
$360.28K
+78.8%
Velleca Mark A.
PRESIDENT & CEO
—
—
—
121,522
0.2115%
$257.25K
—
Jones Erika
SEE REMARKS
—
—
—
85,150
0.1482%
$180.25K
—
Yurasov Sergey
CHIEF MEDICAL OFFICER
—
—
—
75,000
0.1305%
$158.77K
—
Menzel Garry E
Director
—
—
—
51,825
0.0902%
$109.71K
—
Raman Prakash
Director
—
—
—
45,039
0.0784%
$95.34K
—
DIXON WENDY L
Director
—
—
—
38,054
0.0662%
$80.56K
+4,195%
HUMPHREY RACHEL
Chief Medical Officer
—
—
—
10,000
0.0174%
$21.17K
—
Campbell Shannon
Director
—
—
—
8,865
0.0154%
$18.77K
—

Individual transactions

49
Insider
Date
Role
Action
Shares
Price
Amount
Hatzis-Schoch Brent
12 May 2021
See Remarks
Sold after exercise
351
$28.20
$9.90K
Hatzis-Schoch Brent
12 May 2021
See Remarks
Sold after exercise
2,566
$27.90
$71.60K
Hatzis-Schoch Brent
12 May 2021
See Remarks
Sold after exercise
1,161
$26.11
$30.31K
Roberts Christopher D.
3 May 2021
Chief Scientific Officer
Sold after exercise
2,500
$26.64
$66.60K
Hatzis-Schoch Brent
12 Apr 2021
See Remarks
Sold after exercise
4,078
$25.00
$101.95K
Roberts Christopher D.
5 Apr 2021
Chief Scientific Officer
Sold after exercise
2,500
$25.54
$63.85K
Hatzis-Schoch Brent
12 Mar 2021
See Remarks
Sold after exercise
4,078
$26.36
$107.49K
Roberts Christopher D.
3 Mar 2021
Chief Scientific Officer
Sold after exercise
884
$26.57
$23.48K
Roberts Christopher D.
3 Mar 2021
Chief Scientific Officer
Sold after exercise
1,616
$25.85
$41.78K
Hatzis-Schoch Brent
12 Feb 2021
See Remarks
Sold after exercise
307
$27.66
$8.49K
Hatzis-Schoch Brent
12 Feb 2021
See Remarks
Sold after exercise
3,771
$27.19
$102.53K
Roberts Christopher D.
3 Feb 2021
Chief Scientific Officer
Sold after exercise
2,500
$25.35
$63.38K
Hatzis-Schoch Brent
12 Jan 2021
See Remarks
Sold after exercise
7,511
$36.00
$270.40K
Hatzis-Schoch Brent
12 Jan 2021
See Remarks
Sold after exercise
100
$34.13
$3.41K
Hatzis-Schoch Brent
12 Jan 2021
See Remarks
Sold after exercise
103
$32.50
$3.35K
Hatzis-Schoch Brent
12 Jan 2021
See Remarks
Sold after exercise
147
$31.91
$4.69K
Hatzis-Schoch Brent
12 Jan 2021
See Remarks
Sold after exercise
1,669
$30.50
$50.91K
Hatzis-Schoch Brent
12 Jan 2021
See Remarks
Sold after exercise
2,048
$29.92
$61.28K
Leggett Thomas
8 Jan 2021
Chief Financial Officer
Sold after exercise
3,000
$33.94
$101.82K
Epstein David M.
4 Jan 2021
See Remarks
Sold after exercise
2,015
$31.80
$64.07K
Epstein David M.
4 Jan 2021
See Remarks
Sold after exercise
9,985
$30.99
$309.43K
Roberts Christopher D.
4 Jan 2021
Chief Scientific Officer
Sold after exercise
537
$31.78
$17.06K
Roberts Christopher D.
4 Jan 2021
Chief Scientific Officer
Sold after exercise
1,963
$31.31
$61.46K
Hatzis-Schoch Brent
14 Dec 2020
See Remarks
Sold after exercise
4,078
$34.95
$142.52K
Leggett Thomas
8 Dec 2020
Chief Financial Officer
Sold after exercise
1,941
$34.05
$66.09K
Leggett Thomas
8 Dec 2020
Chief Financial Officer
Sold after exercise
1,059
$33.27
$35.23K
Roberts Christopher D.
3 Dec 2020
Chief Scientific Officer
Sold after exercise
2,500
$32.42
$81.06K
Epstein David M.
1 Dec 2020
See Remarks
Sold after exercise
1,077
$33.45
$36.02K
Epstein David M.
1 Dec 2020
See Remarks
Sold after exercise
10,923
$32.64
$356.55K
Hatzis-Schoch Brent
12 Nov 2020
See Remarks
Sold after exercise
250
$35.01
$8.75K
Hatzis-Schoch Brent
12 Nov 2020
See Remarks
Sold after exercise
2,261
$34.24
$77.42K
Hatzis-Schoch Brent
12 Nov 2020
See Remarks
Sold after exercise
1,567
$33.46
$52.44K
Roberts Christopher D.
11 Nov 2020
Chief Scientific Officer
Sold after exercise
5,000
$34.90
$174.50K
Leggett Thomas
9 Nov 2020
Chief Financial Officer
Sold after exercise
3,000
$32.96
$98.89K
Roberts Christopher D.
3 Nov 2020
Chief Scientific Officer
Sold after exercise
2,500
$31.95
$79.87K
Epstein David M.
2 Nov 2020
See Remarks
Sold after exercise
83
$31.88
$2.65K
Epstein David M.
2 Nov 2020
See Remarks
Sold after exercise
11,917
$31.13
$371.01K
Hatzis-Schoch Brent
12 Oct 2020
See Remarks
Sold after exercise
295
$33.75
$9.96K
Hatzis-Schoch Brent
12 Oct 2020
See Remarks
Sold after exercise
3,783
$32.61
$123.37K
Leggett Thomas
8 Oct 2020
Chief Financial Officer
Sold after exercise
3,000
$33.53
$100.58K
Roberts Christopher D.
5 Oct 2020
Chief Scientific Officer
Sold after exercise
227
$31.99
$7.26K
Roberts Christopher D.
5 Oct 2020
Chief Scientific Officer
Sold after exercise
2,273
$31.20
$70.93K
Epstein David M.
1 Oct 2020
See Remarks
Sold after exercise
12,000
$30.33
$363.96K
Leggett Thomas
14 Sep 2020
Chief Financial Officer
Sold after exercise
3,000
$31.00
$93.00K
Hatzis-Schoch Brent
14 Sep 2020
See Remarks
Sold after exercise
207
$32.55
$6.74K
Hatzis-Schoch Brent
14 Sep 2020
See Remarks
Sold after exercise
1,186
$31.42
$37.27K
Hatzis-Schoch Brent
14 Sep 2020
See Remarks
Sold after exercise
2,685
$30.76
$82.58K
Roberts Christopher D.
3 Sep 2020
Chief Scientific Officer
Sold after exercise
2,358
$29.63
$69.88K
Roberts Christopher D.
3 Sep 2020
Chief Scientific Officer
Sold after exercise
142
$28.95
$4.11K
Show all 228 transactions →

What was left out

Form 4 filings counted 245
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 35
Sales on a Rule 10b5-1 plan 1
Sales straight out of an exercise 49
Sales at will 140
Transactions with no price 0
Shares from compensation/vesting 34,697,005
Sales filed before the plan box existed 132
History held since 31 Jan 2020